Some studies have shown that the incorporation of E2 and E5 into the vaccine design may trigger a stronger tumor-specific CD8+ T cell immune response compared to vaccines designed with only E6 and E7 as target antigens [26]. The gene discussed is CD8A; the disease is neoplasm.